The North America Colonoscope Market would witness market growth of 6.3% CAGR during the forecast period (2022-2028).
Colonoscopy is one of the colorectal cancer screening options for Americans aged 45 and older. Other screening procedures include flexible sigmoidoscopy, double-contrast barium enema, computed tomography (CT), colonography (virtual colonoscopy), fecal immunochemical test (FIT), guaiac-based fecal occult blood test (gFOBT), and multitarget stool DNA screening test (Cologuard).
Normal colonoscopies typically have a five- to ten-year memory period. Individuals with a family history of colon cancer are typically checked for the disease for the first time as adolescents. Within five years, the chance of developing colorectal cancer is extremely low for individuals with a first colonoscopy that revealed no abnormalities. Consequently, there is no need for these individuals to get a second colonoscopy before five years have passed since their initial test.
Several medical associations advise those without an increased risk of colorectal cancer in the United States to undergo a screening colonoscopy every ten years beginning at age 50. Research indicates that the risk of cancer is low for ten years if a high-quality colonoscopy does not find cancer; therefore, testing for this is recommended every ten years. Colonoscopy screening protects nearly two-thirds of fatalities related to colorectal malignancies on the left side of the colon. Still, it is not significantly associated with reduced mortality from right-sided disease.
The Centre for Chronic Disease Prevention and Control (CCDPC), a branch of the Public Health Agency of Canada, collaborates with all levels of stakeholders and provides pan-Canadian as well as international governance in chronic disease prevention and management via integrated policy and program development, surveillance, and talent development and dissemination. In Mexico, both males and females have experienced a rise in CRC mortality. Importantly, the mortality records connected with CRC for both sexes increased due to increased sedentary behavior and poor dietary habits. Considering the increasing incidence of CRC, the colonoscope market in North America is predicted to expand.
The US market dominated the North America Colonoscope Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $484.5 Million by 2028. The Canada market is poised to grow at a CAGR of 8.7% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 7.8% during (2022 - 2028).
Based on Application, the market is segmented into Colorectal Cancer, Ulcerative Colitis, Crohns Disease and Others. Based on End User, the market is segmented into Hospitals, Ambulatory Surgery Centers and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide Colonoscope Market is Projected to reach USD 1.7 Billion by 2028, at a CAGR of 6.8%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, Stryker Corporation, Olympus Corporation, Fujifilm Holdings Corporation, Ambu A/S, Boston Scientific Corporation, SonoScape Medical Corp., Daichuan Medical (Shenzhen) Co., Ltd. (EndoFresh), and EndoMed Systems GmbH.
By Application
By End User
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.